Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Cardiol Therapeutics (NASDAQ:CRDL) and raises the price target from $5 to $6.
May 19, 2023 | 11:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains Buy rating on Cardiol Therapeutics and raises price target from $5 to $6.
The news of Canaccord Genuity maintaining a Buy rating and raising the price target for Cardiol Therapeutics is positive for the company's stock. This indicates that the analyst has confidence in the company's growth potential and believes the stock is undervalued. As a result, this news is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100